Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patients

Background The serine protease KLK12 belongs to the human fifteen-member family of kallikrein-related peptidases. Differential expression accompanied by either increased or decreased enzymatic activity has been linked to several diseases including cancer. Triple-negative breast cancer (TNBC) represe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Molecular medicine (Cambridge, Mass.) Ročník 26; číslo 1; s. 19 - 9
Hlavní autoři: Gong, Weiwei, Liu, Yueyang, Preis, Sarah, Geng, Xiaocong, Petit-Courty, Agnes, Kiechle, Marion, Muckenhuber, Alexander, Dreyer, Tobias, Dorn, Julia, Courty, Yves, Magdolen, Viktor
Médium: Journal Article
Jazyk:angličtina
Vydáno: London BioMed Central 07.02.2020
Springer Nature B.V
BMC
Témata:
Age
Angiogenesis
Biomarkers
Biomedical and Life Sciences
Biomedicine
Breast cancer
Cell growth
Estrogens
Gene expression
KLK12
Lymphatic system
Molecular Medicine
mRNA
Polymerase chain reaction
qPCR
Research Article
Statistical analysis
Survival analysis
TNBC
Tumors
United States > US
Germany
qPCR
mRNA
TNBC
KLK12
ISSN:1076-1551, 1528-3658, 1528-3658
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Background The serine protease KLK12 belongs to the human fifteen-member family of kallikrein-related peptidases. Differential expression accompanied by either increased or decreased enzymatic activity has been linked to several diseases including cancer. Triple-negative breast cancer (TNBC) represents a very aggressive subgroup of breast cancer with high tumor recurrence rates and poor patient prognosis. Here, we quantified the KLK12 mRNA expression levels in tumor tissue of TNBC patients and analyzed their prognostic value. Methods In the present study, KLK12 mRNA expression in tumor tissue of TNBC patients ( n  = 116) was determined by quantitative real-time PCR assay. The association of KLK12 mRNA levels with clinical parameters, and patients’ outcome was analyzed using Chi-square tests, Cox regression models and Kaplan-Meier survival analysis. Results Positive, but low KLK12 mRNA levels were detected in about half of the cases (54 out of 116; 47%), the other samples were negative for KLK12 mRNA expression. No significant association was observed between KLK12 mRNA levels and clinicopathological variables (age, lymph node status, tumor size, and histological grade). In univariate Cox analyses, positive KLK12 mRNA expression was significantly associated with shortened disease-free survival (DFS; hazard ratio [HR] = 2.12, 95% CI = 1.19–3.78, p  = 0.010) as well as overall survival (OS; HR = 1.91, 95% CI = 1.04–3.50, p  = 0.037). In multivariable Cox analysis, including all clinical parameters plus KLK12 mRNA, the latter - together with age - remained an independent unfavorable predictive marker for DFS (HR = 2.33, 95% CI = 1.28–4.24, p  = 0.006) and showed a trend towards significance in case of OS (HR = 1.80, 95% CI = 0.96–3.38, p  = 0.066). Conclusions Positive KLK12 expression is remarkably associated with shortened DFS and OS, suggesting that KLK12 plays a tumor-supporting role in TNBC.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1076-1551
1528-3658
1528-3658
DOI:10.1186/s10020-020-0145-7